<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01125475</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 701068-521</org_study_id>
    <nct_id>NCT01125475</nct_id>
  </id_info>
  <brief_title>A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects</brief_title>
  <acronym>SCANSMART</acronym>
  <official_title>A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects: the ScanSmart Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono Norway</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Smerud Medical Research International AS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine adherence to RebifÂ® New Formulation administered by
      RebiSmart during 12 weeks of therapy in patients with RRMS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence assessment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adherence to RNF administered by RebiSmart during 12 weeks of therapy in patients with RRMS</description>
  </primary_outcome>
  <enrollment type="Actual">61</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis (RRMS)</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RebiSmart</intervention_name>
    <description>Treatment with Rebif New Formulation using RebiSmart.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Neurology Clinics at Danish and Norwegian hospitals (single treatment group)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between 18 and 65 years of age

          -  Have relapsing-remitting multiple sclerosis (RRMS) according to the revised McDonald
             Criteria (2005)

          -  Having an expanded disability status scale (EDSS) of less than 6 at the screening
             visit or within 2 months prior to the screening visit

          -  Stable treatment (defined as treatment after titration period) with RebiSmart
             administered Rebif new formulation (RNF) 22/44 mcg subcutaneously thrice a week for a
             minimum of 4 weeks prior to inclusion

          -  Previously treated with disease modifying drugs (DMDs) for a minimum of 6 months prior
             to the screening visit

          -  Female subjects must be neither pregnant nor breast-feeding and must lack
             child-bearing potential as defined by either:

               -  Post-menopausal or surgically sterile; or

               -  Using a highly effective method of contraception for the duration of the study.
                  This is defined as a method that results in a low failure rate (i.e. less than 1%
                  per year) when used consistently and correctly , and includes for instance
                  implants, injectables, combined oral contraceptives, intra-uterine device (IUD),
                  sexual abstinence or vasectomized partner

          -  Have a scheduled visit 12 weeks after the inclusion visit

          -  Willing and able to comply with the protocol for the duration of the study

          -  Have given written informed consent

        Exclusion Criteria:

          -  Have had a relapse within 30 days prior to the first visit

          -  Have any contra-indications to treatment with Interferon-beta 1a according to Summary
             of Product Characteristics

          -  Have any other significant disease that in the Investigator's opinion would exclude
             the subject from the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sandvika Nevrosenter</name>
      <address>
        <city>Sandvika</city>
        <state>Sandviksveien 178</state>
        <zip>N-1337</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2010</study_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing Remitting Multiple Sclerosis</keyword>
  <keyword>RebiSmart</keyword>
  <keyword>Rebif</keyword>
  <keyword>Adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

